ストックスクリーナーアプリを入手
148.39
2.47%
3.58
プレマーケット:
147.51
-0.88
-0.59%
前日終値:
$144.81
開ける：
$147.04
24時間の取引高:
177.19K
Relative Volume:
0.72
時価総額：
$4.27B
収益：
$241.52M
当期純損益:
$52.37M
株価収益率:
83.37
EPS:
1.78
ネットキャッシュフロー:
$58.06M
1週間 パフォーマンス:
-2.96%
1か月 パフォーマンス:
-12.22%
6か月 パフォーマンス:
-28.42%
1年 パフォーマンス:
+17.78%
1日の値動き範囲:
$145.87
$149.15
1週間の範囲:
$141.72
$152.94
52週間の値動き範囲:
$107.50
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
名前
Krystal Biotech Inc
セクター
電話
(412) 586-5830
住所
2100 WHARTON STREET, PITTSBURGH, PA
KRYS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
148.39 | 4.27B | 241.52M | 52.37M | 58.06M | 1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-06 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-11-20 | 開始されました | Goldman | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-12 | 開始されました | Citigroup | Buy |
| 2023-09-07 | 開始されました | Berenberg | Buy |
| 2023-04-18 | 開始されました | Stifel | Buy |
| 2023-02-28 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-25 | ダウングレード | Goldman | Buy → Neutral |
| 2022-01-18 | 開始されました | BofA Securities | Buy |
| 2021-07-20 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-18 | 開始されました | B. Riley FBR | Buy |
| 2020-06-04 | 開始されました | Evercore ISI | Outperform |
| 2019-09-24 | 開始されました | Goldman | Neutral |
| 2019-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-24 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-06-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-30 | 開始されました | Guggenheim | Buy |
| 2018-09-11 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Krystal Biotech Inc (KRYS) 最新ニュース
Short Interest in Krystal Biotech, Inc. (NASDAQ:KRYS) Drops By 8.9% - MarketBeat
Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Down 8.9% in December - Defense World
GAMMA Investing LLC Lowers Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Jeune Aesthetics names new CFO ahead of Phase 2 trials - Investing.com
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer - The Manila Times
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer - GlobeNewswire Inc.
JPMorgan Chase & Co. Has $23.28 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
JPMorgan Chase & Co. Has $23.28 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
City Therapeutics Appoints Andy Orth as Chief Executive Officer - Marketscreener.com
Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today - Benzinga
(KRYS) Proactive Strategies - Stock Traders Daily
Analysts Set Krystal Biotech, Inc. (NASDAQ:KRYS) Target Price at $206.67 - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy (NASDAQ:KRYS) - Seeking Alpha
Principal Financial Group Inc. Sells 3,743 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
(KRYS) Technical Pivots with Risk Controls - Stock Traders Daily
3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings Growth - Simply Wall St
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Yahoo Finance
Avalon GloboCare (NASDAQ:ALBT) vs. Krystal Biotech (NASDAQ:KRYS) Head-To-Head Analysis - Defense World
Krystal Biotech (KRYS) – Research Analysts’ Weekly Ratings Changes - Defense World
Chardan Capital Reaffirms “Buy” Rating for Krystal Biotech (NASDAQ:KRYS) - Defense World
Krystal Biotech reports success with inhalable lung cancer drug in early-stage trial - Mugglehead
KRYS Reports Upbeat Initial Data From Lung Cancer Study Of KB707 - Barchart
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707 - Yahoo Finance
Geode Capital Management LLC Purchases 11,411 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer - Marketscreener.com
Wellington Management Group LLP Buys 1,660 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech reports promising lung cancer trial results By Investing.com - Investing.com Australia
Krystal Biotech Reports Positive Results for KYANITE-1 Study - TipRanks
Krystal Biotech (NASDAQ:KRYS) Given "Buy" Rating at Chardan Capital - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Shares Gap UpWhat's Next? - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Receives "Buy" Rating from HC Wainwright - MarketBeat
Krystal Biotech reports promising lung cancer trial results - Investing.com
Krystal Biotech, Inc.'s (NASDAQ:KRYS) Popularity With Investors Is Under Threat From Overpricing - Simply Wall St
Franklin Resources Inc. Has $43.77 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Teachers Retirement System of The State of Kentucky Increases Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Lord Abbett & CO. LLC Sells 108,079 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech CEO Krishnan sells shares worth $4.12 million By Investing.com - Investing.com South Africa
Krystal Biotech's president Suma Krishnan sells $8.2 million in stock By Investing.com - Investing.com South Africa
Suma Krishnan Sells 25,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock - MarketBeat
Krystal Biotech CEO Krishnan sells shares worth $4.12 million - Investing.com
Krystal Biotech's president Suma Krishnan sells $8.2 million in stock - Investing.com
KRYS Stock Down On Initial Clinical Updates On KB407 & KB408 - Barchart
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408 - MSN
Krystal Biotech announces initial update for KB408, KB407 - Yahoo Finance
Expert Ratings For Krystal Biotech - Benzinga
Krystal Biotech Reports Promising Results for Genetic Medicine - TipRanks
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels - The Manila Times
Krystal Biotech, Inc. Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 - Marketscreener.com
State Street Corp Purchases 119,936 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
HC Wainwright Reaffirms Buy Rating for Krystal Biotech (NASDAQ:KRYS) - MarketBeat
Krystal Biotech Inc (KRYS) 財務データ
収益
当期純利益
現金流量
EPS
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):